AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
AAPL   380.02 (-0.71%)
MSFT   212.22 (-0.98%)
AMZN   3,177.64 (-0.16%)
NVDA   419.09 (-0.30%)
CGC   16.50 (+3.00%)
BABA   256.99 (-1.75%)
MU   50.04 (+0.12%)
GE   6.66 (+1.22%)
TSLA   1,389.03 (-0.38%)
AMD   56.73 (-0.93%)
T   29.65 (+0.37%)
F   5.87 (+0.34%)
GILD   75.79 (+1.45%)
DIS   117.65 (+0.71%)
BAC   23.09 (+1.41%)
NFLX   517.84 (+1.99%)
BA   173.38 (+0.06%)
Log in

NASDAQ:RETAReata Pharmaceuticals Stock Price, Forecast & News

$155.98
-0.15 (-0.10 %)
(As of 07/10/2020 10:09 AM ET)
Add
Compare
Today's Range
$155.16
Now: $155.98
$157.60
50-Day Range
$126.30
MA: $155.34
$176.56
52-Week Range
$70.00
Now: $155.98
$257.96
Volume14,667 shs
Average Volume525,373 shs
Market Capitalization$5.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.03
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Read More
Reata Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.52 million
Book Value$7.74 per share

Profitability

Net Income$-290,170,000.00
Net Margins-1,542.06%

Miscellaneous

Employees123
Market Cap$5.18 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

How has Reata Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RETA shares have decreased by 1.2% and is now trading at $155.9750. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Reata Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Reata Pharmaceuticals.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Reata Pharmaceuticals.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals Inc (NASDAQ:RETA) issued its quarterly earnings results on Monday, May, 11th. The company reported ($1.47) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.98) by $0.51. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $1.28 million. Reata Pharmaceuticals had a negative net margin of 1,542.06% and a negative return on equity of 322.36%. The firm's quarterly revenue was down 82.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.98) EPS. View Reata Pharmaceuticals' earnings history.

What price target have analysts set for RETA?

9 brokerages have issued 1 year target prices for Reata Pharmaceuticals' stock. Their forecasts range from $130.00 to $348.00. On average, they expect Reata Pharmaceuticals' stock price to reach $255.11 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View analysts' price targets for Reata Pharmaceuticals.

Has Reata Pharmaceuticals been receiving favorable news coverage?

Press coverage about RETA stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Reata Pharmaceuticals earned a news impact score of 1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Reata Pharmaceuticals.

Who are some of Reata Pharmaceuticals' key competitors?

What other stocks do shareholders of Reata Pharmaceuticals own?

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:
  • Mr. J. Warren Huff, Chairman, CEO & Pres (Age 65)
  • Dr. Colin J. Meyer, Chief Medical Officer & Exec. VP of Product Devel. (Age 40)
  • Dr. Keith W. Ward, Consultant (Age 49)
  • Mr. Jason D. Wilson, CFO & Exec. VP of Strategy (Age 49)
  • Ms. Elaine Castellanos, VP of Fin. & Accounting

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.01%), Envestnet Asset Management Inc. (0.01%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View institutional ownership trends for Reata Pharmaceuticals.

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Warren Huff, and Jason Douglas Wilson. View insider buying and selling activity for Reata Pharmaceuticals.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, and Envestnet Asset Management Inc.. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, and James W Traweek Jr. View insider buying and selling activity for Reata Pharmaceuticals.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $155.98.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $5.18 billion and generates $26.52 million in revenue each year. The company earns $-290,170,000.00 in net income (profit) each year or ($9.54) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at 972-865-2219 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.